Ozempic®, Wegovy® and Mounjaro® are brand names for Semaglutide (Ozempic® and Wegovy®) and Tripeptide Tirzepatide (Mounjaro®), respectively. Ozempic® is FDA approved to lower blood sugar levels in adults with type 2 diabetes mellitus, in addition to diet and exercise as well as to reduce the risk of heart attack, stroke, or death in adults with type 2 diabetes mellitus and known heart disease. While it is not FDA approved for weight loss, it is used off-label for weight loss. Wegovy® is FDA approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity. Mounjaro® is FDA approved for blood sugar control in type 2 diabetics as well as weight loss.

While the compounded versions also contain Semaglutide and Tirzepatide, the compounded versions are not FDA approved. However, the compounding pharmacies used by Effecty source semaglutide and tirzepatide with the same chemical makeup as the brand name versions.